IMFINZI (durvalumab) Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival for High-Risk Non-Muscle-Invasive Bladder Cancer in POTOMAC Phase III Trial
May 10, 2025
May 10, 2025
WILMINGTON, Delaware, May 10 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
IMFINZI (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus C . . .
* * *
IMFINZI (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus C . . .